ArticleCell chemical biology2022
Cytidine acetylation yields a hypoinflammatory synthetic messenger RNA.
Article in Cell chemical biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 33 citations in OpenAlex.
- Glutathione-Responsive Acyl-Modifications for Targeted RNA Decaging and Prolonged Protein Synthesis.Angewandte Chemie (International ed. in English) · 2026Article
- Review
- Beyond the Sequence: Chemical and Topological Design and Innovations in mRNA Therapeutics.Chemical reviews · 2026Review
- A comprehensive analysis of the use of nucleoside analogues in RNA therapeutics.Journal of translational medicine · 2026Review
- Seven wonders of RNA modification biology.RNA (New York, N.Y.) · 2026Review
- Advances in RNA modification in myocardial fibrosis (Review).International journal of molecular medicine · 2025Review
- The function of NAT10-driven N4-acetylcytidine modification in cancer: novel insights and potential therapeutic targets.Cell & bioscience · 2025Review
- Emerging roles of RNA N4-acetylcytidine modification in reproductive health.Protein & cell · 2025Review
- NAT10 andScience advances · 2025Article
- A sequence-specific RNA acetylation catalyst.Nucleic acids research · 2025Article
- Role of NAT10-mediated acBMC pulmonary medicine · 2025Article
- Nucleic acid drugs: recent progress and future perspectives.Signal transduction and targeted therapy · 2024Review
- A sequence-specific RNA acetylation catalyst.bioRxiv : the preprint server for biology · 2024Article
- Site-specific N-alkylation of DNA oligonucleotide nucleobases by DNAzyme-catalyzed reductive amination.Nucleic acids research · 2024Article
- DNAzyme-Catalyzed Site-Specific N-Acylation of DNA Oligonucleotide Nucleobases.Angewandte Chemie (International ed. in English) · 2024Article
- Cytidine Acetylation Across the Tree of Life.Accounts of chemical research · 2024Article
- NAT10 mediated ac4C acetylation driven mCell communication and signaling : CCS · 2024Article
- Epigenetic and gene therapy in human and veterinary medicine.Environmental epigenetics · 2024Review
- DLC-ac4C: A Prediction Model for N4-acetylcytidine Sites in Human mRNA Based on DenseNet and Bidirectional LSTM Methods.Current genomics · 2023Article
- Self-assembly of DNA-gold nanoaggregate for visual detection of thymidine kinase 1 (TK1) mRNA via lateral flow assay.Mikrochimica acta · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
Synthetic messenger RNA (mRNA) is an emerging therapeutic platform with important applications in oncology and infectious disease. Effective mRNA medicines must be translated by the ribosome but not trigger a strong nucleic acid-mediated immune response. To expand the medicinal chemistry toolbox for these agents, here we report the properties of the naturally occurring nucleobase N
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.